No worries. The tcm here couldn't possibly be the same tcm there. Got it! However, both tcm's have come up with a random number of 10M Outstanding Shares (OS) issued - from doubling the current OS - to the pending OS (3.5M) - to instead QUINTUPLING (10M) the current OS - as some sort of loyalty reward for shareholders. I think it's the kookiest thing I've read yet about the Nasdaq uplist - to include bonuses for management (What the fuuu)?
Sir, I applied simple math in my previous post as one overwhelmingly EZ to understand example of why that idea would help absolutely no one. I will leave it to others to come to their own conclusions. Furthermore, I believe everyone who reads this msg board already knows how to navigate their way to other Algernon message boards to read and/or opine. You make it seem as if the internet itself is a newly discovered phenomenon.
Just to add further clarity here as if it's necessary:
tcm - "...will make a difference in PPS and allow for a larger MC to do stuff as the IPO unfolds."
What I gather is YOU STILL do not understand that the IPO is etched in stone to the point the Market Cap is irrelevant to raising further capital in the immediate future. The 8.4M USD is the number they will come away with (actually it's 7.4M USD).
Now go back and look at the SEC F1/A filing to see how much of that money is to be allocated for Chronic Cough. It shows 500k is going towards ANOTHER Phase 2 trial in Australia. Not only that, it's not a standalone Chronic Cough study. It's including IFP which Moron Moreau himself said is a bad idea.
Yet...here they are again doing the same thing over again in a country that he knows will slow roll enrollment. Algernon Pharmaceuticals is being ran by natural born losers.
Expect another capital raise in 2023 if any of the Phase 1's come away with any data subject to further pursuit. Given "safety" is the only hurdle at Phase 1, surely you can expect "AGNP" will soon become a shorts Dream Dilution Machine on steroids for years to come.
Someone ask Beer Buddy when does he expect a Phase 2 Chronic Cough study to start in Australia - and when does he expect it to end. Then add at least 1 year to whatever answer spews out of his mouth.
Note that Bellus Health ran their USA standalone Phase 2 Chronic Cough clinical trial in less than one year from beginning to Final Data Readout. Remember that everytime Moreau mentions them as a pure comparison.
Mark this post.
M$
